必须做得更好:解决美国注射吸毒者丙型肝炎治疗障碍
美国阿片类流行病及减害服务不足导致丙型肝炎病毒(HCV)感染急剧上升。尽管有证据表明HCV治疗对注射吸毒者(PWID)有效且指南推荐优先治疗,但系统、提供者和患者层面存在多重障碍。消除障碍的干预包括减害服务、简化HCV检测算法、改善与HCV护理服务的衔接,以及在物质使用障碍治疗项目中整合服务等新治疗模式。
要点
- 注射吸毒者(PWID)中HCV感染因阿片类流行病和减害服务不足而急剧上升。
- 指南推荐优先治疗PWID,但系统、提供者和患者层面存在多重障碍。
- 消除障碍需减害服务、简化检测、改善衔接及整合服务等干预。
核心结论
- 美国需借鉴其他国家经验,消除PWID中HCV治疗障碍以应对阿片类流行病后果。
研究设计与样本
- 本文为综述,总结美国PWID中HCV治疗障碍及干预措施。
主要发现
- 美国阿片类流行病和减害服务不足导致HCV感染急剧上升。
- 尽管证据支持HCV治疗对PWID有效且指南推荐优先治疗,但广泛 uptake 存在多重障碍。
- 障碍存在于系统层面、医疗提供者层面和患者层面。
关键数值与推荐
- 临床指南推荐在PWID中优先治疗HCV。
- 干预措施包括减害服务、简化HCV检测算法、改善与HCV护理服务的衔接、应用新治疗模式如在物质使用障碍治疗项目中整合服务。
临床怎么用
- 应优先为PWID提供HCV治疗,并采取减害服务、简化检测、改善衔接和整合服务等干预。
- 可借鉴其他国家经验消除治疗障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The opioid epidemic in the United States, along with a lack of adequate harm reduction services, has contributed to a sharp rise in hepatitis C virus (HCV) infections. Despite considerable evidence of the effectiveness of HCV treatment in people who inject drugs (PWID), and recommendations from clinical guidelines to prioritize treatment in PWID, there are multiple barriers to broad uptake of HCV treatment. These barriers exist at the systems level, as well as at the level of medical providers and patients. Interventions to remove treatment barriers in the United States include harm reduction services, simplifying HCV testing algorithms, improved linkage to HCV care services, and application of new treatment models including colocating services at substance use disorder treatment programs. By following the lead of other countries who have addressed the barriers to HCV treatment, the United States has opportunities to do better in addressing the consequences of the opioid epidemic, including chronic HCV infection.
引用
- Trooskin SB, Dore G, Kostman J, et al. We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States. J Infect Dis. 2020. PMID: 33245349. doi:10.1093/infdis/jiaa574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。